News & Media

Keep up to date with all of our latest news.

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022 Data…

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022 Data…

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022 Paris, May…

SparingVision Announces Oral Presentation of SPVN06 Data at ASGCT 2022

SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022 Paris, May 3, 2022 –…

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis…

SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference

SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference Paris, January 6…

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer…

SparingVision to Present at Upcoming Investor Conferences

SparingVision to Present at Upcoming Investor Conferences Paris, December 3, 2021 – SparingVision (or the…

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Cambridge, MA, and Paris, France– October 13, 2021 Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading…

SparingVision Conference Participation in H2 2021

SparingVision announces the scientific and investor conferences that its management team will be participating in…

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

SparingVision is pleased to announce that it will present a poster highlighting the Company’s recent…

News & Media Menu

LATEST TWEETS

SparingVisionFollow

Genomic medicine company developing vision-saving treatments for ocular diseases #vision #blindness #genetherapy #biotech #healthtech

Avatar SparingVision @SparingVision·

19 May

Today, we will be sharing positive pharmacology and safety #data highlighting the progress of our lead asset SPVN06, a breakthrough mutation-agnostic #genetherapy approach targeting #IRDs, at the @ASGCTherapy 25th Annual Meeting 2022. Find out more here: https://bit.ly/3wu8sxO

Reply on Twitter 1527247851499270145 Retweet on Twitter 15272478514992701454 Like on Twitter 15272478514992701458 Twitter 1527247851499270145

Avatar SparingVision @SparingVision·

17 May

Our CFO Stanislas Piot and Senior Director of IR Nathalie Delair-Trepo are meeting with #investors and industry peers this week (16-18 May) at the #BioEquityEurope Conference hosted by @BioCentury in Milan. More here: https://conferences.biocentury.com/bioequity-europe-2022

Reply on Twitter 1526477625128275968 Retweet on Twitter 1526477625128275968 Like on Twitter 15264776251282759684 Twitter 1526477625128275968

PARTNERS

01

Home

03

Patients

02

Technologies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others